New York State Common Retirement Fund Buys 816,671 Shares of Heron Therapeutics, Inc. $HRTX

New York State Common Retirement Fund raised its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 46.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,576,716 shares of the biotechnology company’s stock after purchasing an additional 816,671 shares during the period. New York State Common Retirement Fund owned 1.41% of Heron Therapeutics worth $3,247,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. ProShare Advisors LLC raised its stake in Heron Therapeutics by 23.4% during the 2nd quarter. ProShare Advisors LLC now owns 31,368 shares of the biotechnology company’s stock worth $65,000 after buying an additional 5,953 shares during the period. Richmond Brothers Inc. lifted its holdings in shares of Heron Therapeutics by 1.8% in the 2nd quarter. Richmond Brothers Inc. now owns 554,469 shares of the biotechnology company’s stock worth $1,148,000 after purchasing an additional 9,568 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Heron Therapeutics by 5.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 241,048 shares of the biotechnology company’s stock valued at $499,000 after purchasing an additional 11,716 shares during the period. B. Riley Wealth Advisors Inc. bought a new stake in Heron Therapeutics during the 2nd quarter valued at $26,000. Finally, R Squared Ltd acquired a new position in Heron Therapeutics during the second quarter worth $26,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Price Performance

Heron Therapeutics stock opened at $1.26 on Friday. Heron Therapeutics, Inc. has a 52 week low of $1.00 and a 52 week high of $2.68. The company’s 50 day moving average price is $1.34 and its two-hundred day moving average price is $1.33. The stock has a market cap of $231.03 million, a P/E ratio of -14.00 and a beta of 1.25. The company has a quick ratio of 1.78, a current ratio of 2.56 and a debt-to-equity ratio of 19.89.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Jefferies Financial Group reissued a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday, November 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Heron Therapeutics in a report on Friday, January 9th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $4.50.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.